Assignee
MADRIGAL PHARMACEUTICALS INC
US·18 granted patents·20 pending applications·70 citations·filing 2015–2025
Top patents by PatentIndex Score
38 records- 0195US10376517B2Methods of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2018·Granted Aug 13, 2019·9 cites·25 claims
- 0295US9266861B2Method of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2015·Granted Feb 23, 2016·23 cites·17 claims
- 0394US11564926B2Methods of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2020·Granted Jan 31, 2023·4 cites·24 claims
- 0494US9968612B2Method of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·9 cites·18 claims
- 0592US11806353B2Methods of treating liver disorders or lipid disorders with a THR-beta agonistMADRIGAL PHARMACEUTICALS INC·Filed 2021·Granted Nov 7, 2023·2 cites·17 claims
- 0691US10894050B2Methods of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2019·Granted Jan 19, 2021·5 cites·12 claims
- 0791US9956293B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted May 1, 2018·5 cites·16 claims
- 0888US10117944B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted Nov 6, 2018·7 cites·12 claims
- 0986US11986481B2Method of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2023·Granted May 21, 2024·0 cites·18 claims
- 1085US11090308B2Methods of treating liver disorders or lipid disorders with a THR-beta agonistMADRIGAL PHARMACEUTICALS INC·Filed 2017·Granted Aug 17, 2021·5 cites·11 claims
- 1182US11491145B2Combination therapies comprising targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·1 cites·14 claims
- 1280US2023210856A1Methods of synthesizing thyroid hormone analogs and polymorphs thereofMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1379US2025368626A1Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrileMADRIGAL PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1478US2025074898A1Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrileMADRIGAL PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1576US2024156826A1Methods of treating liver disorders or lipid disorders with a thr-beta agonistMADRIGAL PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1674US2026069598A1Resmetirom for reducing liver volumeMADRIGAL PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1771US2020316090A1Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1870US2023046803A1Combination therapies comprising targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1969US2021140945A1Methods of treating neurological diseases and disordersMADRIGAL PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2067US10722525B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2017·Granted Jul 28, 2020·0 cites·5 claims
- 2167US10675360B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·0 cites·1 claims
- 2267US2026097039A1Methods for treating a fatty liver diseaseMADRIGAL PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2367US2022289749A1Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2466US2024408102A1Resmetirom for reducing liver volumeMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2565US2024423992A1Biomarkers for treating liver disorders with thr-b agonists and related usesMADRIGAL PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2664US2019314528A1Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2761US2025154130A1Novel thr beta analogs and uses thereofMADRIGAL PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2861US2018217130A1Compositions and methods for treating systemic lupus erythematosusMADRIGAL PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2960US10376598B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted Aug 13, 2019·0 cites·7 claims
- 3059US12377104B1Methods for treating a fatty liver diseaseMADRIGAL PHARMACEUTICALS INC·Filed 2025·Granted Aug 5, 2025·0 cites·24 claims
- 3158US10828315B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted Nov 10, 2020·0 cites·2 claims
- 3257US2021085700A1Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3357US2021122740A1Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrileMADRIGAL PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3457US2024307405A1Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disordersMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3556US2024051925A1Methods for preparing pyridazinone derivativesMADRIGAL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3655US11377447B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2018·Granted Jul 5, 2022·0 cites·1 claims
- 3752US10232049B2Targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2016·Granted Mar 19, 2019·0 cites·13 claims
- 3841US2019060473A1Hsp90 inhibitor drug conjugatesMADRIGAL PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MADRIGAL PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →